YTHDF2 Destabilizes M6a-Modified Neural-Specific Rnas to Restrain Differentiation in Induced Pluripotent Stem Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Xio Is a Component of the Drosophila Sex Determination Pathway and RNA N6-Methyladenosine Methyltransferase Complex
Xio is a component of the Drosophila sex determination pathway and RNA N6-methyladenosine methyltransferase complex Jian Guoa,b, Hong-Wen Tangc, Jing Lia,b, Norbert Perrimonc,d,1, and Dong Yana,1 aKey Laboratory of Insect Developmental and Evolutionary Biology, Chinese Academy of Sciences Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, 200032 Shanghai, China; bUniversity of Chinese Academy of Sciences, 100049 Beijing, China; cDepartment of Genetics, Harvard Medical School, Boston, MA 02115; and dHoward Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Contributed by Norbert Perrimon, February 14, 2018 (sent for review December 6, 2017; reviewed by James W. Erickson and Helen Salz) N6-methyladenosine (m6A), the most abundant chemical modifica- reader YT521-B, are required for Drosophila sex determination 6 tion in eukaryotic mRNA, has been implicated in Drosophila sex and Sxl splicing regulation. Further, m A modification sites have determination by modifying Sex-lethal (Sxl) pre-mRNA and facili- been mapped to Sxl introns, thus facilitating Sxl pre-mRNA al- 6 tating its alternative splicing. Here, we identify a sex determina- ternative splicing. Importantly, m A methylation is required in CG7358 xio human dosage compensation by modifying the long noncoding tion gene, , and rename it according to its loss-of- 6 function female-to-male transformation phenotype. xio encodes RNA XIST,suggestingthatmA-mediated gene regulation is an ancient -
Caspases Switch Off M6a RNA Modification Pathway to Reactivate A
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.12.377127; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 6 1 Caspases switch off m A RNA modification pathway to reactivate a 2 ubiquitous human tumor virus 3 Kun Zhang1,2, Yucheng Zhang3, Jun Wan3,4,5 and Renfeng Li1,2,6,7,8* 4 1Philips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth 5 University, Richmond, Virginia, 23298, USA 6 2Department of Oral and Craniofacial Molecular Biology, School of Dentistry, Virginia 7 Commonwealth University, Richmond, Virginia, 23298, USA 8 3Department of Medical and Molecular Genetics, Indiana University School of Medicine, 9 Indianapolis, Indiana, 46202, USA 10 4Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, 11 Indianapolis, Indiana, 46202, USA. 12 5Department of BioHealth Informatics, School of Informatics and Computing, Indiana University 13 – Purdue University at Indianapolis, Indianapolis, Indiana, 46202, USA 14 6Department of Microbiology and Immunology, School of Medicine, Virginia Commonwealth 15 University, Richmond, Virginia, 23298, USA 16 7Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, 23298, USA. 17 8Lead Contact 18 19 *Corresponding author: [email protected] (RL) 20 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.12.377127; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. -
Mutational Landscape Differences Between Young-Onset and Older-Onset Breast Cancer Patients Nicole E
Mealey et al. BMC Cancer (2020) 20:212 https://doi.org/10.1186/s12885-020-6684-z RESEARCH ARTICLE Open Access Mutational landscape differences between young-onset and older-onset breast cancer patients Nicole E. Mealey1 , Dylan E. O’Sullivan2 , Joy Pader3 , Yibing Ruan3 , Edwin Wang4 , May Lynn Quan1,5,6 and Darren R. Brenner1,3,5* Abstract Background: The incidence of breast cancer among young women (aged ≤40 years) has increased in North America and Europe. Fewer than 10% of cases among young women are attributable to inherited BRCA1 or BRCA2 mutations, suggesting an important role for somatic mutations. This study investigated genomic differences between young- and older-onset breast tumours. Methods: In this study we characterized the mutational landscape of 89 young-onset breast tumours (≤40 years) and examined differences with 949 older-onset tumours (> 40 years) using data from The Cancer Genome Atlas. We examined mutated genes, mutational load, and types of mutations. We used complementary R packages “deconstructSigs” and “SomaticSignatures” to extract mutational signatures. A recursively partitioned mixture model was used to identify whether combinations of mutational signatures were related to age of onset. Results: Older patients had a higher proportion of mutations in PIK3CA, CDH1, and MAP3K1 genes, while young- onset patients had a higher proportion of mutations in GATA3 and CTNNB1. Mutational load was lower for young- onset tumours, and a higher proportion of these mutations were C > A mutations, but a lower proportion were C > T mutations compared to older-onset tumours. The most common mutational signatures identified in both age groups were signatures 1 and 3 from the COSMIC database. -
Novel Candidate Genes of Thyroid Tumourigenesis Identified in Trk-T1 Transgenic Mice
Endocrine-Related Cancer (2012) 19 409–421 Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice Katrin-Janine Heiliger*, Julia Hess*, Donata Vitagliano1, Paolo Salerno1, Herbert Braselmann, Giuliana Salvatore 2, Clara Ugolini 3, Isolde Summerer 4, Tatjana Bogdanova5, Kristian Unger 6, Gerry Thomas6, Massimo Santoro1 and Horst Zitzelsberger Research Unit of Radiation Cytogenetics, Helmholtz Zentrum Mu¨nchen, Ingolsta¨dter Landstr. 1, 85764 Neuherberg, Germany 1Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita` Federico II, Naples 80131, Italy 2Dipartimento di Studi delle Istituzioni e dei Sistemi Territoriali, Universita` ‘Parthenope’, Naples 80133, Italy 3Division of Pathology, Department of Surgery, University of Pisa, 56100 Pisa, Italy 4Institute of Radiation Biology, Helmholtz Zentrum Mu¨nchen, 85764 Neuherberg, Germany 5Institute of Endocrinology and Metabolism, Academy of Medical Sciences of the Ukraine, 254114 Kiev, Ukraine 6Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London W12 0HS, UK (Correspondence should be addressed to H Zitzelsberger; Email: [email protected]) *(K-J Heiliger and J Hess contributed equally to this work) Abstract For an identification of novel candidate genes in thyroid tumourigenesis, we have investigated gene copy number changes in a Trk-T1 transgenic mouse model of thyroid neoplasia. For this aim, 30 thyroid tumours from Trk-T1 transgenics were investigated by comparative genomic hybridisation. Recurrent gene copy number alterations were identified and genes located in the altered chromosomal regions were analysed by Gene Ontology term enrichment analysis in order to reveal gene functions potentially associated with thyroid tumourigenesis. In thyroid neoplasms from Trk-T1 mice, a recurrent gain on chromosomal bands 1C4–E2.3 (10.0% of cases), and losses on 3H1–H3 (13.3%), 4D2.3–E2 (43.3%) and 14E4–E5 (6.7%) were identified. -
Analysis of Diet-Induced Differential Methylation, Expression, And
www.nature.com/scientificreports OPEN Analysis of diet-induced diferential methylation, expression, and interactions of lncRNA and protein- Received: 2 March 2018 Accepted: 29 June 2018 coding genes in mouse liver Published: xx xx xxxx Jose P. Silva1 & Derek van Booven2 Long non-coding RNAs (lncRNAs) regulate expression of protein-coding genes in cis through chromatin modifcations including DNA methylation. Here we interrogated whether lncRNA genes may regulate transcription and methylation of their fanking or overlapping protein-coding genes in livers of mice exposed to a 12-week cholesterol-rich Western-style high fat diet (HFD) relative to a standard diet (STD). Deconvolution analysis of cell type-specifc marker gene expression suggested similar hepatic cell type composition in HFD and STD livers. RNA-seq and validation by nCounter technology revealed diferential expression of 14 lncRNA genes and 395 protein-coding genes enriched for functions in steroid/cholesterol synthesis, fatty acid metabolism, lipid localization, and circadian rhythm. While lncRNA and protein-coding genes were co-expressed in 53 lncRNA/protein-coding gene pairs, both were diferentially expressed only in 4 lncRNA/protein-coding gene pairs, none of which included protein- coding genes in overrepresented pathways. Furthermore, 5-methylcytosine DNA immunoprecipitation sequencing and targeted bisulfte sequencing revealed no diferential DNA methylation of genes in overrepresented pathways. These results suggest lncRNA/protein-coding gene interactions in cis play a minor role mediating hepatic expression of lipid metabolism/localization and circadian clock genes in response to chronic HFD feeding. More than 70% of the mammalian genome is transcribed as non-coding RNA (ncRNA) while only 1–2% of the mammalian genome is transcribed as protein-coding RNA1–3. -
N6-Methyladenosine-Dependent Regulation of Messenger RNA Stability
LETTER doi:10.1038/nature12730 N6-methyladenosine-dependent regulation of messenger RNA stability Xiao Wang1, Zhike Lu1, Adrian Gomez1,GaryC.Hon2, Yanan Yue1, Dali Han1,YeFu1, Marc Parisien3, Qing Dai1, Guifang Jia1,4, Bing Ren2, Tao Pan3 & Chuan He1 N6-methyladenosine (m6A) is the most prevalent internal (non-cap) The YTH domain family is widespread in eukaryotes and known to modification present in the messenger RNA of all higher eukaryotes1,2. bind single-stranded RNA with the conserved YTH domain (.60% Although essential to cell viability and development3–5, the exact role identity) located at the C terminus16,17. In addition to previously reported of m6A modification remains to be determined. The recent discovery YTHDF2 and YTHDF314, we also discovered YTHDF1 as another m6A- of two m6A demethylases in mammalian cells highlighted the impor- selective binding protein by using methylated RNA bait containing the tance of m6A in basic biological functions and disease6–8.Herewe known consensus sites of G(m6A)C and A(m6A)C versus unmethy- show that m6A is selectively recognized by the human YTH domain lated control (Extended Data Fig. 1a). Further, highly purified poly(A)- family 2 (YTHDF2) ‘reader’ protein to regulate mRNA degradation. tailed RNAs were incubated with recombinant glutathione-S-transferase We identified over 3,000 cellular RNA targets of YTHDF2, most of (GST)-tagged YTHDF1-3 and then separated by GST-affinity column. which are mRNAs, but which also include non-coding RNAs, with a By using a previously reported liquid chromatography-tandem mass conserved core motif of G(m6A)C. We further establish the role of spectrometry (LC-MS/MS) method7,8, we found that the m6A-containing YTHDF2 in RNA metabolism, showing that binding of YTHDF2 RNAs were greatly enriched in the YTHDF-bound portion and dimin- results in the localization of bound mRNA from the translatable ished in the flow-through portion (Fig. -
Genomic Analysis of Follicular Dendritic Cell Sarcoma by Molecular
Modern Pathology (2017) 30, 1321–1334 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 1321 Genomic analysis of follicular dendritic cell sarcoma by molecular inversion probe array reveals tumor suppressor-driven biology Erica F Andersen1,2, Christian N Paxton2, Dennis P O’Malley3,4, Abner Louissaint Jr5, Jason L Hornick6, Gabriel K Griffin6, Yuri Fedoriw7, Young S Kim8, Lawrence M Weiss3, Sherrie L Perkins1,2 and Sarah T South1,2,9 1Department of Pathology, University of Utah, Salt Lake City, UT, USA; 2Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, UT, USA; 3Department of Pathology, Clarient/ Neogenomics, Aliso Viejo, CA, USA; 4Department of Pathology, M.D. Anderson Cancer Center/University of Texas, Houston, TX, USA; 5Department of Pathology, Massachusetts General Hospital, Boston, MA, USA; 6Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA; 7Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA and 8Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA Follicular dendritic cell sarcoma is a rare malignant neoplasm of dendritic cell origin that is currently poorly characterized by genetic studies. To investigate whether recurrent genomic alterations may underlie the biology of follicular dendritic cell sarcoma and to identify potential contributory regions and genes, molecular inversion probe array analysis was performed on 14 independent formalin-fixed, paraffin-embedded samples. Abnormal genomic profiles were observed in 11 out of 14 (79%) cases. The majority showed extensive genomic complexity that was predominantly represented by hemizygous losses affecting multiple chromosomes. Alterations of chromosomal regions 1p (55%), 2p (55%), 3p (82%), 3q (45%), 6q (55%), 7q (73%), 8p (45%), 9p (64%), 11q (64%), 13q (91%), 14q (82%), 15q (64%), 17p (55%), 18q (64%), and 22q (55%) were recurrent across the 11 samples showing abnormal genomic profiles. -
YTHDF2 (P-13): Sc-162426
SAN TA C RUZ BI OTEC HNOL OG Y, INC . YTHDF2 (P-13): sc-162426 BACKGROUND SOURCE The YTH domain family protein family (YTHDF) includes YTHDF1, YTHDF2 YTHDF2 (P-13) is an affinity purified goat polyclonal antibody raised against and TYHDF3. YTHDF2 (YTH domain family, member 2), also designated high- a peptide mapping within an internal region of YTHDF2 of human origin. glucose-regulated protein 8, CLL-associated antigen KW-14 or renal carcino - ma antigen NY-REN-2, is a 579 amino acid protein that also contains one PRODUCT YTH domain and exists as two alternatively spliced isoforms. Expressed in Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide pancreas, testis and placenta, YTHDF2 has been identified as a transloca - and 0.1% gelatin. tion partner gene for RUNX1 and is encoded by a gene mapping to human chromosome 1p35.3. Human chromosome 1 spans 260 million base pairs, Blocking peptide available for competition studies, sc-162426 P, (100 µg contains over 3,000 genes and comprises nearly 8% of the human genome. pep tide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA). Chromosome 1 houses a large number of disease-associated genes, includ - ing those that are involved in familial adenomatous polyposis, Stickler syn - APPLICATIONS drome, Parkinson’s disease, Gaucher disease, schizophrenia and Usher syn - YTHDF2 (P-13) is recommended for detection of YTHDF2 of mouse, rat and drome. human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein REFERENCES (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution 1. -
ZC3H13 Polyclonal Antibody Product Information
ZC3H13 Polyclonal Antibody Cat #: ABP52728 Size: 30μl /100μl /200μl Product Information Product Name: ZC3H13 Polyclonal Antibody Applications: WB, ELISA Isotype: Rabbit IgG Reactivity: Human, Mouse Catalog Number: ABP52728 Lot Number: Refer to product label Formulation: Liquid Concentration: 1 mg/ml Storage: Store at -20°C. Avoid repeated Note: Contain sodium azide. freeze / thaw cycles. Background: The zinc finger CCCH domain-containing protein 13 (ZC3H13) is a 1668 amino acid protein that contains one C3H1-type zinc finger. ZC3H13 is phosphorylated upon DNA damage, most likely by ATM or ATR. Two isoforms of ZC3H13 exists as a result of alternative splicing events. The gene encoding ZC3H13 maps to chromosome 13, which contains around 114 million base pairs and 400 genes. Key tumor suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections. Application Notes: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB (1:500-1:2000), ELISA (1:10000). Not yet tested in other applications. Storage Buffer: PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. Storage Instructions: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. -
The Neurodegenerative Diseases ALS and SMA Are Linked at The
Nucleic Acids Research, 2019 1 doi: 10.1093/nar/gky1093 The neurodegenerative diseases ALS and SMA are linked at the molecular level via the ASC-1 complex Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gky1093/5162471 by [email protected] on 06 November 2018 Binkai Chi, Jeremy D. O’Connell, Alexander D. Iocolano, Jordan A. Coady, Yong Yu, Jaya Gangopadhyay, Steven P. Gygi and Robin Reed* Department of Cell Biology, Harvard Medical School, 240 Longwood Ave. Boston MA 02115, USA Received July 17, 2018; Revised October 16, 2018; Editorial Decision October 18, 2018; Accepted October 19, 2018 ABSTRACT Fused in Sarcoma (FUS) and TAR DNA Binding Protein (TARDBP) (9–13). FUS is one of the three members of Understanding the molecular pathways disrupted in the structurally related FET (FUS, EWSR1 and TAF15) motor neuron diseases is urgently needed. Here, we family of RNA/DNA binding proteins (14). In addition to employed CRISPR knockout (KO) to investigate the the RNA/DNA binding domains, the FET proteins also functions of four ALS-causative RNA/DNA binding contain low-complexity domains, and these domains are proteins (FUS, EWSR1, TAF15 and MATR3) within the thought to be involved in ALS pathogenesis (5,15). In light RNAP II/U1 snRNP machinery. We found that each of of the discovery that mutations in FUS are ALS-causative, these structurally related proteins has distinct roles several groups carried out studies to determine whether the with FUS KO resulting in loss of U1 snRNP and the other two members of the FET family, TATA-Box Bind- SMN complex, EWSR1 KO causing dissociation of ing Protein Associated Factor 15 (TAF15) and EWS RNA the tRNA ligase complex, and TAF15 KO resulting in Binding Protein 1 (EWSR1), have a role in ALS. -
AAV-Mediated Direct in Vivo CRISPR Screen Identifies Functional Suppressors in Glioblastoma
View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by DSpace@MIT Author manuscript Author ManuscriptAuthor Manuscript Author Nat Neurosci Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 February 14. Published in final edited form as: Nat Neurosci. 2017 October ; 20(10): 1329–1341. doi:10.1038/nn.4620. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma Ryan D. Chow*,1,2,3, Christopher D. Guzman*,1,2,4,5,6, Guangchuan Wang*,1,2, Florian Schmidt*,7,8, Mark W. Youngblood**,1,3,9, Lupeng Ye**,1,2, Youssef Errami1,2, Matthew B. Dong1,2,3, Michael A. Martinez1,2, Sensen Zhang1,2, Paul Renauer, Kaya Bilguvar1,10, Murat Gunel1,3,9,10, Phillip A. Sharp11,12, Feng Zhang13,14, Randall J. Platt7,8,#, and Sidi Chen1,2,3,4,5,6,15,16,# 1Department of Genetics, Yale University School of Medicine, 333 Cedar Street, SHM I-308, New Haven, CT 06520, USA 2System Biology Institute, Yale University School of Medicine, 333 Cedar Street, SHM I-308, New Haven, CT 06520, USA 3Medical Scientist Training Program, Yale University School of Medicine, 333 Cedar Street, SHM I-308, New Haven, CT 06520, USA 4Biological and Biomedical Sciences Program, Yale University School of Medicine, 333 Cedar Street, SHM I-308, New Haven, CT 06520, USA 5Immunobiology Program, Yale University School of Medicine, 333 Cedar Street, SHM I-308, New Haven, CT 06520, USA 6Department of Immunobiology, Yale University School of Medicine, 333 Cedar Street, SHM I-308, -
Familial Bilateral Cryptorchidism Is
Developmental defects J Med Genet: first published as 10.1136/jmedgenet-2019-106203 on 5 June 2019. Downloaded from ORIGINAL RESEARCH Familial bilateral cryptorchidism is caused by recessive variants in RXFP2 Katie Ayers ,1,2 Rakesh Kumar,3 Gorjana Robevska,2 Shoni Bruell,4,5 Katrina Bell,2 Muneer A Malik,6 Ross A Bathgate,4,5 Andrew Sinclair1,2 3 ► Additional material is ABSTRact structure derived from the primitive mesenchyme. published online only. To view Background Cryptorchidism or failure of testicular During the transabdominal phase, the hypertrophy please visit the journal online (http:// dx. doi. org/ 10. 1136/ descent is the most common genitourinary birth defect in and growth of the gubernaculum steers the testis jmedgenet- 2019- 106203). males. While both the insulin-like peptide 3 (INSL3) and to the caudal part of abdomen. The descent of its receptor, relaxin family peptide receptor 2 (RXFP2), the testis requires hormonal factors produced by For numbered affiliations see have been demonstrated to control testicular descent in the fetal testis itself, such as INSL3 and androgens end of article. mice, their link to human cryptorchidism is weak, with no (see Mäkelä et al4 for a review). Several genes and clear cause–effect demonstrated. pathways have been implicated in testicular descent Correspondence to Dr Katie Ayers, Murdoch Objective To identify the genetic cause of a case of and cryptorchidism, mainly from work in mouse 4 Children’s Research Institute, familial cryptorchidism. models. This includes the insulin-like peptide 3 Parkville, VIC 3052, Australia; Methods We recruited a family in which four boys (INSL3) hormone and its receptor, relaxin family katie.